Drugs / Xenon-133
Xenon-133
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03054870 | Sep 2017 → Sep 2020 | — | Cyclomedica Australia PTY Limited | Terminated | Met primary |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT03331302 Comparator | Sep 2018 → Jun 2020 overdue | chronic obstructive pulmonary disease | University of Virginia | Recruiting | No outcome recorded |
| Phase 3 | NCT01458639 Comparator | Aug 2012 → Jun 2015 | pulmonary embolism | Cyclomedica Australia PTY Limited | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xenon-133 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03331302 ↗ |
| Known as | 133Xe | “However, there are currently no data comparing the quantification of relative lung ventilation with 99mTc-Technegas with that performed using the standard approach with...” PMID 39638430 ↗ Jan 2025 |
| Known as | Xe-133 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03054870 ↗ |
| Modality | Diagnostic / imaging agent | “Radioactive ventilation scintigraphy of the lung” NCT03331302 ↗ |
| Route | Inhaled | “Subjects first inhaled active comparator Xe-133” NCT03054870 ↗ |